Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 2/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851033 | 0.77 | RXRA (0.44) | RXRARARGPPARGHMGCRRXRB | |
| SCHEMBL18068 | 0.75 | L3MBTL1 (0.44) | MEN1KMT2A | |
| SCHEMBL10212529 | 0.74 | RXRA (0.46) | RXRARARGPPARGRXRBRXRG | |
| SCHEMBL11264823 | 0.72 | GABRA1 (0.50) | RXRARARGPPARGGABRA1CA12 | |
| SCHEMBL12261433 | 0.71 | GABRA1 (0.46) | GABRA1APLNR | |
| SCHEMBL31079293 | 0.71 | GABRA1 (0.46) | GABRA1APLNR | |
| SCHEMBL4850986 | 0.70 | RXRA (0.41) | RXRARARGPPARGRXRBRXRG | |
| Methoxymethane SCHEMBL27923058 | 0.70 | APLNR (0.43) | GABRA1APLNR | |
| SCHEMBL20018179 | 0.69 | HPGD (0.36) | PPARGAPLNRTSHRKMT2A | |
| SCHEMBL12290810 | 0.69 | MAPT (0.37) | MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1373240-B1 | RETINOID X RECEPTOR MODULATORS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040167160-A1 | Retinoid x receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| EP-1373240-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002071827-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167160-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | RXRA 1/4885RARG 5/4885PPARG 18/4885 |
| US-20080090860-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | RXRA 1/4885RARG 5/4885PPARG 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.